Proteolysis-concentrating on chimeras (PROTACs) and molecular glue degraders (MGDs) are probably the most maturely designed TPD strategies. In this assessment, we target equally preclinical experiments and medical trials to provide a comprehensive summary of the protection and clinical success of PR